Latest news
vTv Therapeutics (VTVT) Stock Rises Despite Widening Losses And Zero Revenue - simplywall.stsimplywall.st · Sat, 08 Aug 2026 05:30:54 GMTvTv Therapeutics (NASDAQ:VTVT) Rating Lowered to "Sell" at Wall Street Zen - MarketBeatMarketBeat · Sat, 08 Aug 2026 05:18:55 GMTVTV THERAPEUTICS, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $42 FROM $45 - BitgetBitget · Fri, 07 Aug 2026 07:43:50 GMTvTv Therapeutics (NASDAQ:VTVT) Posts Earnings Results, Misses Expectations By $0.08 EPS - MarketBeatMarketBeat · Fri, 07 Aug 2026 05:31:30 GMTvTv Therapeutics (VTVT) Advances Diabetes Treatment Amid High Pr - GuruFocusGuruFocus · Fri, 07 Aug 2026 02:20:44 GMTVTVT 8-K & SEC Filings - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 01:44:23 GMTVTVT Maintains Buy Rating -- Price Target Lowered to $42.00 by H - GuruFocusGuruFocus · Thu, 06 Aug 2026 22:08:13 GMTVTVT: Phase 3 CATT1 trial nears enrollment completion as net loss widens on higher R&D spend - TradingViewTradingView · Thu, 06 Aug 2026 20:30:50 GMT